Literature DB >> 19048200

Other inhibitors of viral enzymes and functions.

H Zimmermann1, G Hewlett, H Rübsamen-Waigmann.   

Abstract

Until the end of the 1970s, the mainstays of antiviral chemotherapy were nucleoside analogues that targeted virus polymerase, in particular, the herpesvirus DNA polymerase. The scourge of HIV triggered an unprecedented commitment to identify novel antivirals, and these efforts transformed antiviral therapy into the modern, sophisticated treatment form described in this book, with targets such as the reverse transcriptase and the protease as well as the entry of the human immunodeficiency virus. As the regulation of human pathogenic virus growth cycles became more understandable, the realisation grew that these pathogens had more than one Achilles heel that might be suitable targets for small molecules with antiviral activity. This chapter addresses those "other" targets as well as other approaches to the tried and tested polymerase inhibitors, the so-called non-nucleoside inhibitors of reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19048200      PMCID: PMC7122372          DOI: 10.1007/978-3-540-79086-0_6

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  102 in total

Review 1.  HIV integrase structure and function.

Authors:  D Esposito; R Craigie
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

Review 2.  International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  S G Deeks
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

Review 3.  Cytomegalovirus (CMV) resistance to antivirals.

Authors:  W L Drew; C V Paya; V Emery
Journal:  Am J Transplant       Date:  2001-11       Impact factor: 8.086

4.  The herpes simplex virus type 1 cleavage/packaging protein, UL32, is involved in efficient localization of capsids to replication compartments.

Authors:  C Lamberti; S K Weller
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 5.  HIV-1 integrase: structural organization, conformational changes, and catalysis.

Authors:  E Asante-Appiah; A M Skalka
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

Review 6.  Human cytomegalovirus terminase as a target for antiviral chemotherapy.

Authors:  Elke Bogner
Journal:  Rev Med Virol       Date:  2002 Mar-Apr       Impact factor: 6.989

7.  Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.

Authors:  Linghang Zhuang; John S Wai; Mark W Embrey; Thorsten E Fisher; Melissa S Egbertson; Linda S Payne; James P Guare; Joseph P Vacca; Daria J Hazuda; Peter J Felock; Abigail L Wolfe; Kara A Stillmock; Marc V Witmer; Gregory Moyer; William A Schleif; Lori J Gabryelski; Yvonne M Leonard; Joseph J Lynch; Stuart R Michelson; Steven D Young
Journal:  J Med Chem       Date:  2003-02-13       Impact factor: 7.446

8.  Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.

Authors:  M E Falagas; C Paya; R Ruthazer; A Badley; R Patel; R Wiesner; J Griffith; R Freeman; R Rohrer; B G Werner; D R Snydman
Journal:  Transplantation       Date:  1998-10-27       Impact factor: 4.939

9.  Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses.

Authors:  Peter Borowski; Johanna Deinert; Sarah Schalinski; Maria Bretner; Krzysztof Ginalski; Tadeusz Kulikowski; David Shugar
Journal:  Eur J Biochem       Date:  2003-04

10.  A peptide inhibitor of HIV-1 assembly in vitro.

Authors:  Jana Sticht; Michael Humbert; Stuart Findlow; Jochen Bodem; Barbara Müller; Ursula Dietrich; Jörn Werner; Hans-Georg Kräusslich
Journal:  Nat Struct Mol Biol       Date:  2005-07-24       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.